Drug development platform creator Xbiome has raised nearly $100m in series B funding while bioindustrial startup services provider 21st.Bio secured a similar amount from Novo.
Funding Xbiome, the China-based creator of an artificial intelligence-equipped drug development platform, has raised almost $100m in a series B round featuring Legend Capital, the venture capital firm established by conglomerate Legend Holdings. It was joined in the round by 5Y Capital, Primavera Capital, Gaorong Capital and Hike Capital. Pharmaceutical firm Novo has provided €86m…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
